Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/63029
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2030-12-31
Colecciones
- INI - Artigos de Periódicos [3397]
Metadatos
Mostrar el registro completo del ítem
IMMUNOGENICITY AND SAFETY OF HEPATITIS B VIRUS (HBV) VACCINE WITH A TOLL-LIKE RECEPTOR 9 AGONIST ADJUVANT IN HBV VACCINE-NAÏVE PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS
Autor
Afiliación
Division of Infectious Diseases. Weill Cornell Medicine. New York, New York, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Chulalongkorn University. Faculty of Medicine. Thai Red Cross AIDS Research Centre and CE in Tuberculosis. HIV-NAT. Bangkok, Thailand.
Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. Division of Infectious Diseases. Baltimore, Maryland, USA.
University of Texas. McGovern Medical School, Houston. Division of Infectious Diseases.Texas, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California San Francisco. Department of Medicine. Division of Gastroenterology and Hepatology. San Francisco, California, USA.
University of Zimbabwe. Faculty of Medicine and Health Sciences. Internal Medicine Unit. Harare, Zimbabwe.
DLH Corporation. Silver Spring, Maryland, USA.
Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
University of Cincinnati College of Medicine. Division of Digestive Diseases. Cincinnati, Ohio, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Chulalongkorn University. Faculty of Medicine. Thai Red Cross AIDS Research Centre and CE in Tuberculosis. HIV-NAT. Bangkok, Thailand.
Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. Division of Infectious Diseases. Baltimore, Maryland, USA.
University of Texas. McGovern Medical School, Houston. Division of Infectious Diseases.Texas, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California San Francisco. Department of Medicine. Division of Gastroenterology and Hepatology. San Francisco, California, USA.
University of Zimbabwe. Faculty of Medicine and Health Sciences. Internal Medicine Unit. Harare, Zimbabwe.
DLH Corporation. Silver Spring, Maryland, USA.
Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
University of Cincinnati College of Medicine. Division of Digestive Diseases. Cincinnati, Ohio, USA.
Resumen en ingles
In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.
Compartir